The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Mitosis-targeted anti-cancer therapies: where they stand
Open accessAbstract
The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells. Moreover, these antimitotic drugs are also highly selective and sensitive. Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body's response to these drugs still herald the biggest challenge towards clinical success. Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations. In this review, current antimitotic agents are summarized with particular emphasis on the evaluation of their clinical efficacy as well as their limitations. In addition, we discuss the basis behind the lack of activity of these inhibitors in human trials and the potential and future directions of mitotic anticancer strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen
Mayer, T. U., Kapoor, T. M., Haggarty, S. J., King, R. W., Schreiber, S. L., & Mitchison, T. J. (1999) · Science · doi:10.1126/science.286.5441.971 · Cited by 1,727
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Mitotic kinases as regulators of cell division and its checkpoints
Nigg, E. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35048096 · Cited by 1,547
Cell death by mitotic catastrophe: a molecular definition
Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207528 · Cited by 1,269
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
The cellular geography of Aurora kinases
Carmena, M., & Earnshaw, W. C. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1245 · Cited by 1,139
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Polo-like kinases and the orchestration of cell division
Barr, F. A., Silljé, H. H. W., & Nigg, E. A. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1401 · Cited by 1,087
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
14-3-3σ is required to prevent mitotic catastrophe after DNA damage
Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Nature · doi:10.1038/44188 · Cited by 895
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Dynamics of chronic myeloid leukaemia
Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P., Sawyers, C. L., & Nowak, M. A. (2005) · Nature · doi:10.1038/nature03669 · Cited by 833
Gascoigne, K. E., & Taylor, S. S. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.07.002 · Cited by 832
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
Aneuploidy Acts Both Oncogenically and as a Tumor Suppressor
Weaver, B. A. A., Silk, A. D., Montagna, C., Verdier-Pinard, P., & Cleveland, D. W. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.003 · Cited by 729
Kapoor, T. M., Mayer, T. U., Coughlin, M. L., & Mitchison, T. J. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.5.975 · Cited by 717
Stuck in Division or Passing through
Rieder, C. L., & Maiato, H. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.002 · Cited by 657
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
Li, F., Ackermann, E. J., Bennett, C. F., Rothermel, A. L., Plescia, J., Tognin, S., Villa, A., Marchisio, P. C., & Altieri, D. C. (1999) · Nature Cell Biology · doi:10.1038/70242 · Cited by 600
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
Weaver, B. A. A., & Cleveland, D. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.011 · Cited by 520
Exploring the Functional Interactions between Aurora B, INCENP, and Survivin in Mitosis
Honda, R., Körner, R., & Nigg, E. A. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0769 · Cited by 508
Olie, R. A., Simões‐Wüst, A. P., Baumann, B., Leech, S. H., Fabbro, D., Stahel, R. A., & Zangemeister‐Wittke, U. (2000) · PubMed · Cited by 489
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jackson, J. R., Patrick, D. R., Dar, M. M., & Huang, P. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2049 · Cited by 473
Kops, G. J. P. L., Foltz, D. R., & Cleveland, D. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401142101 · Cited by 437
DNA damage checkpoints in mammals
Niida, H., & Nakanishi, M. (2006) · Mutagenesis · doi:10.1093/mutage/gei063 · Cited by 432
CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment
Wood, K. W., Sakowicz, R., Goldstein, L. S. B., & Cleveland, D. W. (1997) · Cell · doi:10.1016/s0092-8674(00)80419-5 · Cited by 431
Kuukasjärvi, T., Karhu, R., Tanner, M., Kähkönen, M., Schäffer, A. A., Nupponen, N. N., Pennanen, S., Kallioniemi, A. H., Kallioniemi, O., & Isola, J. (1997) · PubMed · Cited by 401
An IAP-IAP Complex Inhibits Apoptosis
Dohi, T., Okada, K., Xia, F., Wilford, C. E., Samuel, T., Welsh, K., Marusawa, H., Zou, H., Armstrong, R., Matsuzawa, S.-I., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400236200 · Cited by 398
Yao, X., Abrieu, A., Zheng, Y., Sullivan, K. F., & Cleveland, D. W. (2000) · Nature Cell Biology · doi:10.1038/35019518 · Cited by 391
Spatial and Temporal Regulation of Condensins I and II in Mitotic Chromosome Assembly in Human Cells
Ono, T., Fang, Y., Spector, D. L., & Hirano, T. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-03-0242 · Cited by 379
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991 · Cited by 365
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Human myeloid leukemia cell lines: a review
Koeffler, H., & Golde, D. (1980) · Blood · doi:10.1182/blood.v56.3.344.344 · Cited by 349
Zeng, X., Sigoillot, F., Gaur, S., Choi, S., Pfaff, K. L., Oh, D.-C., Hathaway, N., Dimova, N., Cuny, G. D., & King, R. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.010 · Cited by 333
How does radiation kill cells?
Cohen–Jonathan, E., Bernhard, E. J., & McKenna, W. G. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80014-3 · Cited by 328
Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells
Janssen, A., Kops, G. J. P. L., & Medema, R. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904343106 · Cited by 313
The spindle checkpoint: tension versus attachment
Pinsky, B. A., & Biggins, S. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.07.005 · Cited by 293
Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly
Huang, H.-C., Shi, J., Orth, J. D., & Mitchison, T. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.020 · Cited by 291
Stacchini, A., Aragno, M., Vallario, A., Alfarano, A., Circosta, P., Gottardi, D., Faldella, A., Rege-Cambrin, G., Thunberg, U., Nilsson, K., et al. (1999) · Leukemia Research · doi:10.1016/s0145-2126(98)00154-4 · Cited by 283
Validating Aurora B as an anti-cancer drug target
Girdler, F., Gascoigne, K. E., Eyers, P. A., Hartmuth, S., Crafter, C., Foote, K. M., Keen, N. J., & Taylor, S. S. (2006) · Journal of Cell Science · doi:10.1242/jcs.03145 · Cited by 282
Craig, R. (2002) · Leukemia · doi:10.1038/sj.leu.2402416 · Cited by 266
Tubulin and microtubules as targets for anticancer drugs.
Hadfield, J. A., Ducki, S., Hirst, N., & McGown, A. T. (2003) · PubMed · Cited by 247
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E
Wood, K. W., Lad, L., Luo, L., Qian, X., Knight, S. D., Nevins, N., Brejc, K., Sutton, D., Gilmartin, A. G., Chua, P. R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915068107 · Cited by 235
Komlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
Chauhan, D., Singh, A. V., Aujay, M., Kirk, C. J., Bandi, M., Ciccarelli, B., Raje, N., Richardson, P., & Anderson, K. C. (2010) · Blood · doi:10.1182/blood-2010-04-276626 · Cited by 209
Kinesin motor proteins as targets for cancer therapy
Huszar, D., Theoclitou, M.-E., Skolnik, J., & Herbst, R. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9185-8 · Cited by 206
Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis
Ko, M. A., Rosario, C. O., Hudson, J. W., Kulkarni, S., Pollett, A., Dennis, J. W., & Swallow, C. J. (2005) · Nature Genetics · doi:10.1038/ng1605 · Cited by 204
Manchado, E., Guillamot, M., de Cárcer, G., Eguren, M., Trickey, M., García-Higuera, I., Moreno, S., Yamano, H., Cañamero, M., & Malumbres, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.028 · Cited by 202
Ku86 is essential in human somatic cells
Li, G., Nelsen, C., & Hendrickson, E. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022649699 · Cited by 200
Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase
Colombo, R., Caldarelli, M., Mennecozzi, M., Giorgini, M. L., Sola, F., Cappella, P., Perrera, C., Depaolini, S. R., Rusconi, L., Cucchi, U., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2101 · Cited by 193
Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells
Xi, G., Hu, X., Wu, B., Jiang, H., Young, C. Y. F., Pang, Y., & Yuan, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.026 · Cited by 193
Weidner, N., Moore II, D. H., & Vartanian, R. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90140-6 · Cited by 190
Mitotic drug targets and the development of novel anti-mitotic anticancer drugs
Schmidt, M., & Bastians, H. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.06.003 · Cited by 186
The case for Survivin as mitotic regulator
Lens, S. M., Vader, G., & Medema, R. H. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.016 · Cited by 184
Securin and B-cyclin/CDK are the only essential targets of the APC
Thornton, B. R., & Toczyski, D. P. (2003) · Nature Cell Biology · doi:10.1038/ncb1066 · Cited by 179
Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy
Wang, Y., Ji, P., Liu, J., Broaddus, R. R., Xue, F., & Zhang, W. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-8 · Cited by 179
Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O., & Burke, D. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2005.1800 · Cited by 177
Marcus, A. I., Peters, U., Thomas, S. L., Garrett, S., Zelnak, A., Kapoor, T. M., & Giannakakou, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413471200 · Cited by 170
Schöffski, P., Awada, A., Dumez, H., Gil, T., Bartholomeus, S., Wolter, P., Taton, M., Fritsch, H., Glomb, P., & Munzert, G. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.001 · Cited by 169
Olmos, D., Barker, D., Sharma, R., Brunetto, A. T., Yap, T. A., Taegtmeyer, A. B., Barriuso, J., Medani, H., Degenhardt, Y. Y., Allred, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2946 · Cited by 169
The ubiquitin system: pathogenesis of human diseases and drug targeting
Ciechanover, A., & Schwartz, A. L. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.018 · Cited by 169
PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity
Soncini, C., Carpinelli, P., Gianellini, L., Fancelli, D., Vianello, P., Rusconi, L., Storici, P., Zugnoni, P., Pesenti, E., Croci, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1964 · Cited by 162
Compartmentalized Phosphorylation of IAP by Protein Kinase A Regulates Cytoprotection
Dohi, T., Xia, F., & Altieri, D. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.004 · Cited by 160
Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line
Lin, J.-P., Yang, J.-S., Lee, J.-H., Hsieh, W.-T., & Chung, J.-G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i1.21 · Cited by 159
Tse, A. N., Rendahl, K. G., Sheikh, T. N., Cheema, H., Aardalen, K., Embry, M. G., Ma, S., Moler, E. J., Ni, Z., de Menezes, D. E. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1424 · Cited by 153
Correcting aberrant kinetochore microtubule attachments: an Aurora B-centric view
Kelly, A. E., & Funabiki, H. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.004 · Cited by 150
Matthews, D. J., Yakes, M., Chen, J., Tadano, M., Bornheim, L. M., Clary, D. O., Tai, A., Wagner, J. M., Miller, N., Kim, Y. D., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3699 · Cited by 141
Spindle Poisons and Cell Fate: A Tale of Two Pathways
Matson, D. R., & Stukenberg, P. T. (2011) · Molecular Interventions · doi:10.1124/mi.11.2.12 · Cited by 136
Eisterer, W., Jiang, X., Christ, O., Glimm, H., Lee, K. H., Pang, E., Lambie, K., Shaw, G., Holyoake, T. L., Petzer, A. L., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403649 · Cited by 135
Choi, E. J., & Kim, G. (2008) · Phytomedicine · doi:10.1016/j.phymed.2008.04.006 · Cited by 133
Jimeno, A., Li, J., Messersmith, W. A., Laheru, D. A., Rudek, M. A., Maniar, M. L., Hidalgo, M. M., Baker, S. D., & Donehower, R. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9788 · Cited by 128
Brown, J. R., Koretke, K. K., Birkeland, M. L., Sanséau, P., & Patrick, D. R. (2004) · BMC Evolutionary Biology · doi:10.1186/1471-2148-4-39 · Cited by 122
Cyclin/cdk complexes: Their involvement in cell cycle progression and mitotic division
John, P. C. L., Mews, M., & Moore, R. H. (2001) · PROTOPLASMA · doi:10.1007/bf02673865 · Cited by 120
Shankar, S. L., Mani, S., O’Guin, K., Kandimalla, E. R., Agrawal, S., & Shafit‐Zagardo, B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00596.x · Cited by 109
Survivin in Solid Tumors: Rationale for Development of Inhibitors
Church, D. N., & Talbot, D. C. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0215-2 · Cited by 107
Khoury, J. D., Medeiros, L. J., Rassidakis, G. Z., McDonnell, T. J., Abruzzo, L. V., & Lai, R. L. (2002) · The Journal of Pathology · doi:10.1002/path.1254 · Cited by 100
Syljuåsen, R. G., Sørensen, C. S., Nylandsted, J., Lukas, C., Lukas, J., & Bartek, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2434 · Cited by 99
Human Cancer Cells Commonly Acquire DNA Damage during Mitotic Arrest
Dalton, W. B., Nandan, M. O., Moore, R. T., & Yang, V. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5162 · Cited by 88
Walsby, E. J., Walsh, V., Pepper, C. J., Burnett, A. K., & Mills, K. (2008) · Haematologica · doi:10.3324/haematol.12148 · Cited by 88
Mross, K. B., Dittrich, C., Aulitzky, W. E., Strumberg, D., Schütte, J., Schmid, R. M., Hollerbach, S., Merger, M., Munzert, G. M., Fleischer, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.257 · Cited by 86
Hikichi, Y., Honda, K., Hikami, K., Miyashita, H., Kaieda, I., Murai, S., Uchiyama, N., Hasegawa, M., Kawamoto, T., Sato, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0762 · Cited by 81
Joshi, K., Rathos, M. J., Mahajan, P., Wagh, V., Shenoy, S. S., Bhatia, D. R., Chile, S., Sivakumar, M., Maier, A., Fiebig, H., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0614 · Cited by 74
Schafer-Hales, K. J., Iaconelli, J., Snyder, J. P., Prussia, A. J., Nettles, J. H., El‐Naggar, A. K., Khuri, F. R., Giannakakou, P., & Marcus, A. I. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0703 · Cited by 71
Raje, N. S., Hideshima, T., Mukherjee, S., Raab, M. S., Vallet, S., Chhetri, S., Cirstea, D. D., Pozzi, S., Mitsiades, C. S., Rooney, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.378 · Cited by 68
Amadori, D., Volpi, A., Maltoni, R., Nanni, O., Amaducci, L., Amadori, A., Giunchi, D. C., Vio, A., Saragoni, A., & Silvestrini, R. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005780107879 · Cited by 66
Burris, H. A., Jones, S. F., Williams, D. D., Kathman, S. J., Hodge, J. P., Pandite, L. N., Ho, P. T. C., Boerner, S. A., & LoRusso, P. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9374-x · Cited by 62
Kim, E. H., Lee, H., Lee, D.-H., Bae, S., Soh, J., Jeoung, D., Kim, J., Cho, C.-K., Lee, Y.-J., & Lee, Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4344 · Cited by 59
Li, T., Christensen, S., Frankel, P. H., Margolin, K. A., Agarwala, S. S., Luu, T. H., Mack, P. C., Lara, P. N., & Gandara, D. R. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9562-8 · Cited by 58
Theoclitou, M., Aquila, B. M., Block, M. H., Brassil, P. J., Castriotta, L., Code, E. L., Collins, M. P., Davies, A. M., Deegan, T. L., Jayachandran, E., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200629m · Cited by 48
Souid, A., Dubowy, R. L., Ingle, A. M., Conlan, M. G., Sun, J., Blaney, S. M., & Adamson, P. C. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22609 · Cited by 47
Tcherniuk, S. O., van Lis, R., Kozielski, F., & Skoufias, D. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.001 · Cited by 47
Ellis, P. M., Chu, Q. S.-C., Leighl, N. B., Laurie, S. A., Fritsch, H., Gaschler‐Markefski, B., Gyorffy, S., & Munzert, G. M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.04.003 · Cited by 46
Rhabdoid Tumor Growth is Inhibited by Flavopiridol
Smith, M., Cimica, V., Chinni, S., Challagulla, K., Mani, S., & Kalpana, G. V. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1347 · Cited by 45
Smith, P. J., Syed, N., & Crook, T. (2006) · Cell Cycle · doi:10.4161/cc.5.12.2813 · Cited by 41
Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
Mohammad, R. M., Mohamed, A., Hamdan, M. Y., Vo, T. D., Chen, B., Katato, K., Abubakr, Y., Dugan, M. C., & Al-Katib, A. M. (1996) · PubMed · Cited by 39
Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy
Smolders, L., & Teodoro, J. G. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.558008 · Cited by 37
Infante, J. R., Kurzrock, R., Spratlin, J. L., Burris, H. A., Eckhardt, S., Li, J., Wu, K., Skolnik, J. M., Hylander-Gans, L., Osmukhina, A., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1667-z · Cited by 37
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells
Shen, L., Au, W., Wong, K., Shimizu, N., Tsuchiyama, J., Kwong, Y., Liang, R. H. S., & Srivastava, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0641 · Cited by 36
Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside
Mato, A. R., Feldman, T. A., & Goy, A. H. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0341 · Cited by 36
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
Cresta, S., Sessa, C., Catapano, C. V., Gallerani, E., Passalacqua, D., Rinaldi, A., Bertoni, F., Viganò, L., Maur, M., Capri, G., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.022 · Cited by 35
Li, Y., Tanaka, K., Xu, L., Okada, T., Nakamura, T., Takasaki, M., Yamamoto, S., Oda, Y., Tsuneyoshi, M., & Iwamoto, Y. (2007) · International Journal of Cancer · doi:10.1002/ijc.22820 · Cited by 34
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Kummar, S., Gutierrez, M. E., Gardner, E. R., Figg, W. D., Melillo, G., Dancey, J. E., Sausville, E. A., Conley, B. A., Murgo, A. J., & Doroshow, J. H. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1154-y · Cited by 34
Increasedl-arginine transport in a nitric oxide-producing metastatic colon cancer cell line
Cendan, J. C., Souba, W. W., Copeland, E. M., & Lind, D. S. (1996) · Annals of Surgical Oncology · doi:10.1007/bf02305770 · Cited by 32
Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death
Lai, S.-K., Wong, C. H., Lee, Y.-P., & Li, H. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.165 · Cited by 31
Self-citationGonzález-Moreno, Ó., Calvo, A., Joshi, B. H., Abasolo, I., Leland, P., Wang, Z., Montuenga, L. M., Puri, R. K., & Green, J. E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20789 · Cited by 31
Einsele, H. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_12 · Cited by 30
Hendrickson, A. E. W., Oberg, A. L., Glaser, G. E., Camoriano, J. K., Peethambaram, P. P., Colón‐Otero, G., Erlichman, C., Ivy, S. P., Kaufmann, S. H., Karnitz, L. M., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.002 · Cited by 29
Bae, S. H., Ryoo, H.-M., Kim, M. S., Lee, K., Sin, J., & Hyun, M. (2008) · Oncology Reports · doi:10.3892/or.19.4.1027 · Cited by 27
Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy.
Anderson, H. J., Andersen, R. J., & Roberge, M. (2003) · PubMed · Cited by 25
Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma
Szende, B., Romics, I., Minik, K., Szabó, J., Torda, I., Lovász, S., Szomor, L., Tóth, L., Bely, M., Kerënyi, T., et al. (2001) · The Prostate · doi:10.1002/pros.1122 · Cited by 25
The Centrosome: A Target for Cancer Therapy
Mazzorana, M., Montoya, G., & Mortuza, G. B. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795655949 · Cited by 19
Ku, J., Kim, K., Choi, J.-S., Jeon, Y.-K., Kim, S.-H., Shin, Y., Kim, T., Bang, Y., Kim, W. H., & Park, J. (2011) · Cellular Oncology · doi:10.1007/s13402-010-0004-6 · Cited by 9
Cited by
Targeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
Label-free cell cycle analysis for high-throughput imaging flow cytometry
Blasi, T., Hennig, H., Summers, H. D., Theis, F. J., Cerveira, J., Patterson, J. O., Davies, D., Filby, A., Carpenter, A. E., & Rees, P. (2016) · Nature Communications · doi:10.1038/ncomms10256 · Cited by 299
Teo, R. D., Hwang, J. Y., Termini, J., Gross, Z., & Gray, H. B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00400 · Cited by 289
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Metadata
- Authors
- Chan, K.-S., Koh, C.-G., & Li, H.-Y.
- Venue
- Cell Death & Disease
- Published
- 2012-10-18
- Volume
- 3
- Issue
- 10
- Pages
- e411-e411
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W1978985990
- Cited by
- 305
- References
- 116
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.